Ipilimumab/nivolumab

Myasthenia gravis, hepatitis and thyroiditis: case report

    This is a preview of subscription content, log in to check access.

    Reference

    1. Leaver PJ, et al. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease. BMJ Case Reports 13: No. 5, May 2020. Available from: URL: http://doi.org/10.1136/bcr-2019-232920

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Ipilimumab/nivolumab. Reactions Weekly 1810, 122 (2020). https://doi.org/10.1007/s40278-020-80142-2

    Download citation